Nektar Therapeutics (NKTR) Q3 2024 earnings summary

Executive summary

• Advanced immunology and inflammation pipeline with rapid enrollment in Phase IIb studies for rezpegaldesleukin (REZPEG) in atopic dermatitis and alopecia areata, with topline data expected in 2025.

• Announced sale of Huntsville manufacturing facility for $90 million ($70M cash, $20M equity), strengthening financial position and expected to close by December 2, 2024.

• Published and presented promising clinical and preclinical data for REZPEG and NKTR-255 in dermatology and oncology indications.

• Restructuring in 2022 and 2023 led to significant workforce reductions and focus on core R&D programs.

• Regained full rights to rezpegaldesleukin from Eli Lilly and initiated two Phase IIb studies.

Financial highlights

• Q3 2024 revenue was $24.1 million, flat year-over-year; nine-month revenue rose to $69.3 million.

• Q3 2024 net loss was $37.1 million ($0.18/share), improved from $45.8 million ($0.24/share) in Q3 2023; nine-month net loss narrowed to $126.2 million.

• Cash and investments totaled $249 million at September 30, 2024, down from $329.4 million at year-end 2023.

• Sale of manufacturing facility to add $90 million ($70M cash, $20M equity), extending cash runway into Q4 2026.

• Operating costs and expenses in Q3 2024 were $58.5 million, down from $69.0 million in Q3 2023, mainly due to lower restructuring and impairment charges.

Outlook and guidance

• Cash and investments expected to fund operations into Q4 2026, covering key data milestones.

• Topline data for REZPEG Phase IIb in atopic dermatitis expected in H1 2025; alopecia areata in H2 2025.

• Full-year 2024 R&D expense guidance: $120M–$130M; G&A: $75M–$80M.

• At least one early-stage program (NKTR-0165 or NKTR-0166) planned to enter the clinic in 2025.

• Gain of $40M–$45M expected from facility sale in Q4 2024, with no tax liability.